Aakha Biologics Secures Key Funding to Advance Revolutionary Lung Cancer Therapies
Aakha Biologics, an innovative biotechnology company, has secured a $2.55 million seed grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and a $0.4 million Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI). These funds will accelerate the development of their immune therapy for advanced non-small cell lung cancer (NSCLC). Aakha's therapy uses mono or bispecific antibodies to block a newly validated cancer target from tumor cells, restoring immune surveillance. This approach aims to eliminate tumor cells by recruiting natural killer (NK) cells and cytotoxic T cells. The CPRIT grant will support IND-enabling studies of AHA-1031, an ADCC-enhanced monospecific antibody, while the SBIR grant will develop a novel bispecific immune cell engager.
Aakha Biologics Secures Key Funding to Advance Revolutionary Lung Cancer Therapies